Panelists discuss how MEK inhibitors, such as trametinib and selumetinib, are emerging as first-line treatments for symptomatic NF1-associated plexiform neurofibromas, especially in progressive or ...

EMA committee recommends marketing approval for SpringWorks’ mirdametinib to treat adult & paediatric patients with NF1-PN: Stamford, Connecticut Tuesday, May 27, 2025, 12:00 Hr ...

Pasithea Therapeutics has announced the start of a Phase I/Ib open-label trial of macrocyclic mitogen-activated protein kinase (MEK) inhibitor, PAS-004, for treating adults with neurofibromatosis type ...

If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for ...

Neurofibromatosis 1-associated plexiform neurofibromas (NF1-PN) are benign tumors that develop along peripheral nerves throughout the body. They are typically present at birth or develop in early ...

Neurofibromatosis type 1 (NF1) is a genetic condition that raises your risk of tumors, including benign plexiform neurofibromas (PN), which grow along tissues that cover nerves. PN often can’t ...

These clinically meaningful data show KOSELUGO has the potential to make a positive impact in patient care by reducing the size of plexiform neurofibromas." Marc Dunoyer, chief executive officer ...

The FDA approved Gomekli for patients aged 2 years and older diagnosed with neurofibromatosis type 1 and symptomatic plexiform neurofibromas not amenable to complete resection. Image: Adobe Stock ...

“There are no treatments for many NF1 symptoms; current treatments for NF1 plexiform neurofibromas, such as surgery and MEK inhibitors, are helpful but come with their own set of trade ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

The trial aims to provide insights on both plexiform and cutaneous neurofibromas and is supported by an anticipated Australian R&D Tax Incentive refund of up to 48.5% of eligible costs.